To Observe The Safety And Clinical Efficacy Of Immunotherapy Combined With Targeted Therapy In The Conversion Therapy Of Advanced Liver Cancer

Cancer is the leading cause of human death and poses a serious economic burden.Cancer has also become a serious public health problem in China.Primary liver cancer is now the fourth most common malignant tumor and the second most lethal cause of cancer in China,posing a serious threat to the life and health of Chinese people.Most of the patients with liver cancer have hepatitis B virus infection and the background of cirrhosis caused by it.Most of the patients are in the middle and late stage of diagnosis,with complex disease and poor prognosis.The patients have few surgical opportunities,low radical resection rate,and high postoperative complications and mortality.In 2007,the appearance of Sorafenib opened the prelude of targeted therapy,and in 2017,Lun Vatinib was approved as a first-line drug.With more and more studies,the combination of immune targeted therapy gradually entered people’s vision,opening a new chapter in the treatment of liver cancer.Objective: To investigate the efficacy of immunotherapy combined with targeted drugs in the transformation therapy of advanced hepatocellular carcinoma.Methods: Data of patients diagnosed in our hospital and receiving immunization combined with targeted drug intervention from January 2019 to December 2022 were collected,and eligible patients were selected as research objects.All patients eventually included in the study were followed up for at least 12 months.Follow-up was carried out by telephone consultation,online communication platform communication,face-to-face communication,etc.Obtain the basic data of cases,blood routine and other indicators.Then process and summarize this,and then make further statistical analysis.On this basis,draw the total survival curve,and calculate the incidence of adverse reactions based on the previous statistical results,and the efficacy and safety of the combined drug strategy were discussed.Results: After excluding the unqualified patients,a total of 27 patients participated in this study.When evaluating the curative effect of patients,this article mainly uses mRECIST as the evaluation basis.According to statistics,8 cases of disease progression,accounting for 13% of the total number of patients,12 cases of stable disease,accounting for 56.6% of the total number of patients,6 cases of partial remission,accounting for 26.1%of the total number of patients,and 1 case of significant treatment effect,accounting for 4.3% of the total number of patients.Further calculation showed that the objective remission rate was 25.9%,and 70.4% of the patients were under effective control,median overall survival 12.0(95% confidence interval 8.6-15.4)months.All patients experienced adverse reactions during treatment using NCI-CTC 5.0 criteria.Most of the adverse reactions were mild.No serious adverse reactions resulting in death were observed.The common adverse reactions were abnormal liver function(81.5%,n=22),hypertension(59.3% n=16),fever,fatigue(48.1% n=13),leukopenia(40.7%,n=11),gastrointestinal reactions(33.3%,n=9),thrombocytopenia(29.6%,n=8),Hypothyroidism(22.2%,n=6),rash(22.2%,n=6),hand and foot syndrome(18.5%,n=5),albuminuria(3.7%,n=1).Grade 3 and above were hypertension(29.6%,n=8),abnormal liver function(14.8%,n=4),thrombocytopenia(7.4%,n=2),leukopenia(7.4%,n=2),and rash(3.7%,n=1).By the deadline for follow-up(01/01/2023),12 patients had died and 15 were still alive.Conclusions: The combination therapy has a definite effect,can improve the objective response rate to a large extent,and is conducive to the remission of the disease,and has high safety and high patient satisfaction,which is worth promoting in practice.